Introduction {#Sec1}
============

Brain metastases are increasingly common and cause significant morbidity and mortality in patients with solid tumours \[[@CR1]--[@CR4]\]. Recent analyses of the brain--brain metastasis interface \[[@CR5], [@CR6]\] suggest local invasion may be more important than previously thought \[[@CR7]\] and various solutions including supra-marginal surgical resection and cavity boost stereotactic radiosurgery (SRS) have been proposed \[[@CR8]--[@CR10]\]. MRI scans of the brain are routinely obtained in the course of diagnosis and disease monitoring for these patients and diffusion MRI (DWI) sequences are commonly included, historically to distinguish these ring enhancing tumours from abscesses but more recently to aid in differentiating solitary metastases from glioma, for surgical planning and even to predict prognosis \[[@CR11]\]. It is known that in human brain metastases the apparent diffusion coefficient (ADC) increases with decreasing cellularity \[[@CR12]\] and decreasing density of intratumoral connective tissue \[[@CR13]\]. Changes in ADC in the peritumoral brain may precede micro-metastasis appearance in animal models \[[@CR14]\] and lower tumour ADC values have been shown to be predictive of earlier recurrence and shorter survival after neurosurgery \[[@CR12], [@CR13]\] and SRS \[[@CR15]\]. The aim of this study was to investigate whether the addition of an ADC map to a standard post-contrast T1 weighted sequence would aid SRS planning, in terms of increasing the final planned treatment volume or potentially encompassing peritumoral areas where local recurrence subsequently occurred.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

In this retrospective study, 17 consecutive neurosurgical patients (median age 54 years, 4 male/13 female) with a supratentorial brain metastasis who had undergone diffusion-weighted MRI (DWI) as part of their preoperative investigations and who had developed recurrence at the site of surgery (as per generic RANO criteria \[[@CR16]\]) were included (Table [1](#Tab1){ref-type="table"} **)**. All patients studied underwent gross total resection and there were no complications within 30 days of operation. Median overall survival was 11.8 months (95% CI 7.8--15.8 months) and median time to local recurrence was 8.0 months (95% CI 6.6--9.4 months).

Table 1Demographic and clinical information of the included patientsIDAge (years)SexPerformance status (KPS) (%)GPA categoryPrimary cancerExtracranial metastasesStatus of primary tumourLocation of brain metastasisM01138F1003.0Melanoma (BRAF+)PresentStable diseaseOccipitalM01348F903.5--4.0NSCLCAbsentStable diseaseFrontalM01970F901.5--2.5Lung NOSPresentSynchronousCerebellarM02857F701.5--2.5MelanomaPresentSynchronousParietalM03170M903.0NSCLCAbsentStable diseaseOccipitalM03336F1003.5--4.0NSCLCAbsentSynchronousTemporalM04260F701.5--2.5UnknownPresentSynchronousFrontalM05248F903.0Breast (HER2−)PresentStable diseaseParietalM22256F903.5--4.0NSCLCAbsentStable diseaseFrontalM30235F903.0Melanoma (BRAF+)PresentStable diseaseParietalM00854F803.0NSCLCAbsentSynchronousFrontalM25768M903.0NSCLCAbsentSynchronousParietalM26067M903.0NSCLCAbsentSynchronousOccipitalM26851M903.5--4.0NSCLCAbsentStable diseaseFrontalM30856F903.5--4.0Breast (HER2+)AbsentStable diseaseFrontalM13527F903.5--4.0Breast (HER2−)AbsentStable diseaseParietalM16453F1001.5--2.5NSCLCPresentSynchronousFrontal

MRI and analysis {#Sec4}
----------------

MR imaging was performed on clinical whole body scanners at 1.5T with a single channel head coil. The standard post-contrast T1-weighted sequence was a volumetric fast spoiled gradient echo sequence, which was acquired after the intravenous administration of Gadavist® (Bayer HealthCare, Germany) at a standard dose of 0.1 mmol/kg. The acquisition parameters were as follows: repetition time (TR) 9 ms, echo time (TE) 1.4 ms, flip angle 15 degrees, acquisition matrix 256 × 256, volume 180 × 1 mm axial slices at zero angulation. DWI was obtained using one acquisition over 90 s through single-shot echo planar imaging with b values of 0 and 1000 s/mm^2^. Using the post processing software package GE FuncTool^®^ (v 4.5.5, General Electric Co., Maryland, USA), an ADC map was generated for each dataset. All patients underwent a control volume CT brain on day 1 post operatively as per institutional protocol.

Stereotactic radiosurgery planning {#Sec5}
----------------------------------

Scans were transferred to Oncentra MasterPlan^®^ (Nucletron BV, Veenendaal, Netherlands) and target delineation performed in a randomized reading order by three separate operators experienced in SRS planning and blinded to the clinical information and outcome of the patient. Different imaging sequences were contoured at different days in order to avoid pre-imaging bias. Volumetric analysis was done within MasterPlan^®^ employing the "Case Explorer" tool. We compared treatment volumes based on the post-contrast T1-weighted scans (GTV~T1gad~), using the ADC maps alone (GTV~ADC~) and using both sequences in combination, which we subsequently refer to as diffusion treatment volume (DTV) and then compared these with areas of subsequent recurrence after gross total resection. The conformity index is a concept in radiation oncology used to compare treatment plans and volumes and has a variety of derivations and applications. Here an intentionally simple approach is used, calculating the ratio of intersection of two volumes with their combined total volume to yield an index of their conformity from 0, no similarity whatsoever, to 1, identical plans (illustrated in Fig. [1](#Fig1){ref-type="fig"}).

Fig. 1Illustration of the conformity index (=intersection volume ÷ conjunction volume) for comparing treatment volumes based on the T1gad and the ADC studies

Results {#Sec6}
=======

Clinical outcomes {#Sec7}
-----------------

All patients studied underwent gross total resection with no complications within 30 days of operation. Median overall survival was 11.8 months (95% CI 7.8--15.8 months) and median time to local recurrence was 8.0 months (95% CI 6.6--9.4 months). In fifteen of seventeen cases neurosurgical resection of a solitary cerebral metastasis was followed by adjuvant whole brain radiotherapy (WBRT) 30 Gy in 10 fractions. In one case the patient was too unwell due to systemic disease to receive WBRT and in one other 20 Gy in 5 fractions was administered at the treating oncologists' discretion. At recurrence five patients underwent re-operation, three underwent SRS and the remainder received palliative chemotherapy.

Assessing treatment volumes {#Sec8}
---------------------------

Intra-class correlation coefficient showed strong agreement amongst the three different observers; for GTV~T1gad~ alpha = 0.998 (95% CI 0.992--0.999) and for GTV~ADC~ alpha = 0.987 (95% CI 0.958--0.997). Direct pairwise comparison of GTV~T1gad~ and GTV~ADC~ showed no quantitative difference (related samples Wilcoxon signed rank test = −0.45, p = 0.653); values are listed in Table [2](#Tab2){ref-type="table"}. The conformity index (Fig. [1](#Fig1){ref-type="fig"}) was used to qualitatively compare the volumes; mean conformity index (±SD) for GTV~T1gad~ compared to GTV~ADC~ was 0.53 (±0.16), which is significantly different from 1 (one sample *t* test, t = −11.9, df = 16, p \< 0.001). As a control, the conformity index for GTV~T1gad~ of different observers was calculated and found to be 0.79 (±0.28) with no significant difference from 1 (p \> 0.05).

Table 2Average metastasis volume as assessed using the standard post-contrast planning sequence (T1gad) and the ADC mapCase IDGTV~T1gad~GTV~ADC~DTV (union of GTV~T1gad~ and GTV~ADC~)M01118.529.8130.46M01310.212.5713.65M01938.9927.8844.82M02812.339.414.23M03149.4842.3555.36M03316.0310.0716.89M04271.7164.5177.21M0524.334.275.77M2227.276.89.31M30214.1818.5819.87M0082.351.52.37M2574.415.486.70M2600.750.490.84M2684.857.568.18M3089.527.0512.45M1358.7415.0616.35M1641.191.742.24Median9.529.4013.65Volumes are in cm^3^

Combining the ADC map with standard planning {#Sec9}
--------------------------------------------

The DTV was significantly greater than the GTV~T1gad~ both quantitatively (related samples Wilcoxon signed rank test = 3.621, p \< 0.001) and qualitatively (conformity index = 0.74 (±0.17), significantly different to 1, t = −6.27, p = 0.001). There was no significant difference in the volume of recurrent tumour that would have been covered by the GTV~T1gad~ vs. the GTV~ADC~ (3.53 and 3.57 cm^3^ respectively, Wilcoxon related samples test = −0.052, p = 0.959) and the conformity index was not significantly different (0.20 ± 0.16 for GTV~ADC~ vs. 0.22 ± 0.20 for GTV~T1gad~, paired *t* test = 0.823, p = 0.424). The volume of recurrence encompassed by the DTV was significantly greater than the GTV~T1gad~ in 12 of 16 individual cases as well as overall for the group (median 3.84 cc, range 0--32, vs. 3.53 cc, range 0--31), Wilcoxon related samples test = −3.061, p = 0.002; this is illustrated for one case (M-011) in Fig. [2](#Fig2){ref-type="fig"}.

Fig. 2An occipital metastasis in a patient with metastatic melanoma (M-011). Treatment plans were generated based on **a** the ADC map---GTV~ADC~ and **b** the post-contrast T1-weighted planning study---GTV~T1gad~. The combined plan with addition of these two volumes is termed the diffusion treatment volume or DTV (**c**). These volumes are superimposed on post-contrast T1-weighted sequences acquired at the point when the resected tumour recurred. The volume of local recurrence that was covered by the GTV~T1gad~ (**d**) was less than that covered by the DTV (**e**) and differed in conformation

Discussion {#Sec10}
==========

We have shown that using an ADC map in addition to a conventional post-contrast T1-weighted MRI sequence to plan radiosurgery for solitary brain metastases results in a greater treatment volume with a different conformation compared to the standard protocol. Furthermore, this combined treatment volume intersects with a greater volume of subsequent local recurrence of that metastasis following complete resection. This analysis suggests the ADC map to provide additional, different, clinically useful information compared to the post-contrast T1-weighted sequence alone.

Local recurrence occurs in approximately 20% of cases following radiosurgery \[[@CR17]\] and poses a clinical problem for patients and clinicians. ADC is known to decrease with increasing cellularity. Unlike arbitrarily increasing the treated volume, which has not consistently been shown to reduce local recurrence \[[@CR18]\] and may risk radionecrosis to normal brain \[[@CR19]\], using the ADC map to plan SRS may therefore cover biologically active areas, although it is likely that ADC changes represent a generalized overall assessment of the underlying biological and pathological processes. ADC changes have been used in a radiotherapy planning study to distinguish high-risk areas for glioblastoma recurrence \[[@CR20]\]; however, to our knowledge DWI has never been applied to metastasis radiosurgery planning before. The only investigations into SRS planning for brain metastases that focussed on combining metabolic with anatomic imaging by using FDG-PET \[[@CR21], [@CR22]\]; this study resulted in modified treatment plans for 2/3 of brain metastases in a series of 8 lesions. One further study fitted 11-C methionine PET to the contrast-enhancing border \[[@CR23]\] using a simple model to provide metabolic tumour delineation, but did not look at outcome parameters.

There are limitations to our study that need to be taken into account when interpreting the data. Our study design is retrospective in nature, which, however, offered the advantage of a complete follow-up from time of diagnosis to death. Further prospective studies could evaluate SRS planning based on the ADC map and the post-contrast T1-weighted MRI followed by comparison of subsequent local recurrence with the original plans. Nevertheless, our pilot study confirms that diffusion-based plans were of reasonable quality and detail. Moreover, the extent of coverage of such plans in regard to surrounding brain tissue and the technical integration of diffusion-weighted imaging into a planning software could be demonstrated. At this point in time, ADC may not routinely be added for GTV definition in SRS as normal tissue constraints have to be considered and tumour volumes tend to be larger when applying the DTV concept as presented. However, if our preliminary data are confirmed in future studies, this limitation may be overcome by hypo-fractionated stereotactic treatments as the risk--benefit ratio will be improved with increasing tumour size.
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